Editas Medicine (EDIT) in its earnings release last night announced an expanded oncology collaboration with Juno Therapeutics, a unit of Celgene (CELG). The expanded collaboration with Celgene will develop and commercialize chimeric antigen receptor and engineered T cell receptor medicines including Celgene’s lead program for human papillomavirus-associated solid tumors, Editas said in a statement. As a result of the expansion and progress of the collaboration, Editas will receive an additional $10M in cash and will be eligible to receive a fourth independent milestone and royalty stream. Shares of Editas Medicine are up 10%, or $3.12, to $34.72 in early trading.
previous post
next post